In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...

Fans can vote through early morning of Dec. 22 for their favorite boys and girls in the latest Marion Star Athlete of the ...

Playing in just its second home contest of the season, the Bowling Green Christian Academy’s varsity boys basketball team ...

A strong third-quarter perfomance by Northmor pushed them past visiting Centerburg on Wednesday by a 55-47 margin.

Mount Gilead hosted its first home meet of the season on Wednesday, Jan. 10, against Marion Pleasant, Kenton, Elgin, Buckeye Valley, Wynford and Ridgemont. Kenton won the meet, with the Indians ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...

Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...